Trial Review

Please note that the ANZCTR will be unattended on Friday 25th April due to the ANZAC Day public holiday. Submissions and updates will not be processed during that time.

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.



Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06442462




Registration number
NCT06442462
Ethics application status
Date submitted
29/05/2024
Date registered
4/06/2024
Date last updated
18/04/2025

Titles & IDs
Public title
Study of SPG302 in Adults With Schizophrenia
Scientific title
A Randomized, Placebo-controlled, Double-blind Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacodynamics of SPG302 in Adult Participants Diagnosed With Schizophrenia
Secondary ID [1] 0 0
SPG302-SCZ-201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Schizophrenia 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Schizophrenia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SPG302
Treatment: Drugs - Placebo

Active comparator: Active SPG302 to be administered to participants with Schizophrenia - Participants with schizophrenia will be randomized to receive SPG302 300 mg or placebo (two capsules of 150 mg) once daily for six weeks.

Placebo comparator: Placebo comparator to be administered to participants with Schizophrenia - Participants with schizophrenia will be randomized to receive SPG302 300 mg or placebo (two capsules of 150 mg) once daily for six weeks.


Treatment: Drugs: SPG302
small synthetic molecule

Treatment: Drugs: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Positive and Negative Symptoms Scale (PANSS Score) as determined by clinician
Timepoint [1] 0 0
6 weeks
Primary outcome [2] 0 0
Electroencephalogram analysis to assess brain electrical activity
Timepoint [2] 0 0
6 weeks
Primary outcome [3] 0 0
Change in smooth pursuit eye tracking from baseline
Timepoint [3] 0 0
6 weeks
Secondary outcome [1] 0 0
Safety and tolerability of SPG302 in patients with schizophrenia
Timepoint [1] 0 0
6 weeks
Secondary outcome [2] 0 0
Change in Global Impressions Improvement scale as determined by clinician
Timepoint [2] 0 0
6 weeks
Secondary outcome [3] 0 0
Change in MATRICS Consensus Cognitive Battery scale as determined by clinician
Timepoint [3] 0 0
6 weeks
Secondary outcome [4] 0 0
World Health Organization Quality of Life - Abbreviated Assessment Questionnaire-brief version from baseline
Timepoint [4] 0 0
6 weeks
Secondary outcome [5] 0 0
Change in Personal and Social Performance from baseline
Timepoint [5] 0 0
6 weeks

Eligibility
Key inclusion criteria
* Age 18-65
* Primary diagnosis of schizophrenia
* Clinical laboratory values within normal range or < 1.5 times ULN
* Currently prescribed only one antipsychotic medication, with stable dose for at least 4 weeks
* Able and willing to provide written informed consent
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any physical or psychological condition that prohibits study completion
* Known cardiac disease
* Active or history of malignancy in the past 5 years
* History of clinically significant CNS event or diagnosis in the past 5 years.
* Receipt of investigational products within 30 days
* Blood donation within 30 days

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/10/2025
Actual
Sample size
Target
32
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Box Hill Hospital - Eastern Health - Box Hill
Recruitment hospital [2] 0 0
Multidisciplinary Alfred Psychiatry Research Centre (MAPrc) - Melbourne
Recruitment postcode(s) [1] 0 0
3128 - Box Hill
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Spinogenix
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Rebecca Ho, MD
Address 0 0
Multidisciplinary Alfred Psychiatry Research Centre (MAPrc)
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Contact Spinogenix
Address 0 0
Country 0 0
Phone 0 0
+61 3 9076 6913
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06442462